Trevi Therapeutics
CompanyUnited States
Trevi Therapeutics develops one asset, in phase 3 (Nalbuphine in idiopathic pulmonary fibrosis). Mostly small molecule acting on OPRM1 and OPRK1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 2
- Trials
- 2
- Signals
Pipeline
1Activates kappa opioid receptors and antagonizes mu opioid receptors to suppress chronic cough.
Phase 3, Small molecule, OPRM1, OPRK1, idiopathic pulmonary fibrosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Signals3
- Similar companies6